Sign in

Research summary ·

Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This meta-analysis looked at cardiac myosin inhibitors (CMIs) in obstructive hypertrophic cardiomyopathy (oHCM). It focused on cardiac magnetic resonance (CMR) findings. The team searched PubMed, Cochrane Library and Embase up to July 27, 2025. It used random-effects models to pool mean differences. Mavacamten and aficamten were both included in all outcomes. A few randomized trials with 150 patients were included. They compared CMIs with placebo.

What they found

CMIs cut left ventricular mass index. The MD was -20.01 g/m2 (CI -29.77 to -10.26). I2 was 67.7. They also cut maximal left ventricular wall thickness. The MD was -2.66 mm (CI -3.53 to -1.79). Left atrial volume index fell too (MD -13.02, CI -17.17 to -8.87). These P values were under 0.0001. Late gadolinium enhancement did not clearly improve (MD 0.54, P = 0.2973). Extracellular volume fraction did not fall significantly (MD 1.43, P = 0.0528).

What it means for patients

The paper says CMIs improve cardiac structure in oHCM. It says the effect on myocardial fibrosis remains unclear.

Why it is not certain yet

The paper says the effect on myocardial fibrosis remains unclear. Only a few trials were pooled. A review can only be as good as the studies in it.

Source

Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes.

PubMed · PMID 42715826

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Hypertrophic cardiomyopathy publications